Latest Innovation News

Lloyds Banking Group reported a resilient start to 2025 with statutory profit after tax of £1.1 billion, underpinned by solid lending and deposit growth. The bank reaffirmed its 2025 guidance, maintaining confidence despite economic uncertainties.

Clean TeQ Water has landed a A$1.2 million engineering contract to design a DESALX® wastewater treatment plant for Nyrstar's European operations, paving the way for a potential A$9.4 million project stage.

HitIQ Limited's trading suspension has been lifted following its announcement of a proposed capital raising, signaling renewed investor interest and potential growth opportunities.

Andromeda Metals has successfully produced ultra-high purity alumina (HPA) at 99.9985% purity using a novel, cost-effective, and lower carbon process from kaolin sourced at its Great White Project. Independent validation confirms the breakthrough, positioning the company to capitalize on growing global demand.

Sparc Technologies has successfully raised up to A$2.7 million through a share placement and a Share Purchase Plan, positioning the company to accelerate commercialisation of its graphene additive ecosparc and support its green hydrogen pilot projects.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.

ClearVue Technologies has secured its first commercial rooftop contract in Sydney’s CBD, supplying innovative solar glass for the City Tattersalls Club redevelopment to boost sustainability and energy efficiency.

Nanoveu Limited has successfully raised $2.3 million through a share placement to accelerate development and commercialization of its cutting-edge semiconductor, 3D visualization, and solar coating technologies.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.